0001209191-23-058971.txt : 20231218 0001209191-23-058971.hdr.sgml : 20231218 20231218164629 ACCESSION NUMBER: 0001209191-23-058971 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231214 FILED AS OF DATE: 20231218 DATE AS OF CHANGE: 20231218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nolan Sean P. CENTRAL INDEX KEY: 0001569926 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 231494412 MAIL ADDRESS: STREET 1: C/O INTERMUNE, INC. STREET 2: 3280 BAYSHORE BLVD. CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-14 0 0001806310 Taysha Gene Therapies, Inc. TSHA 0001569926 Nolan Sean P. C/O TAYSHA GENE THERAPIES, INC. 3000 PEGASUS PARK DRIVE, SUITE 1430 DALLAS TX 75247 1 1 0 0 Chief Executive Officer 0 Employee Stock Option (right to buy) 0.6989 2023-12-14 4 A 0 466550 0.00 A 2033-12-14 Common Stock 466550 466550 D The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ Kamran Alam, Attorney-in-Fact 2023-12-18